LONDON, March 18, 2013 /PRNewswire/ -- Smith & Nephew (LSE: SN NYSE: SNN), the global medical technology business, is set to showcase its advanced portfolio of medical devices at this year's American Academy of Orthopaedic Surgeons (AAOS) meeting in Chicago, March 19-23.
New products highlighted at the show include the recently launched REDAPT™ Hip Revision System, the JOURNEY™ II BCS Knee, which incorporates VERILAST™ Technology in a knee replacement system that restores the anatomical shapes and more normal motion of the human knee, and a new Modular Rail System for deformity correction and limb restoration that was designed in collaboration with Dror Paley, MD.
Further illustrating the company's increased, strategic investment in fast-growing areas of the orthopaedic market is the ALL28™ foot and ankle portfolio, and a suite of industry-leading sports medicine technologies, including the FAST-FIX™ 360 Meniscal Repair System, the DYONICS™ Platinum Series Blades, and HEALICOIL™ PK, BIORAPTOR™ and OSTEORAPTOR™ Suture Anchors for joint repair.
Also highlighted will be the company's Advanced Wound Management (AWM) surgical incision management portfolio, led by the single-use, pocket-sized PICO™ Negative Pressure Wound Therapy system, one of a number of AWM products that can help reduce orthopaedic surgical site complications, such as dehiscence or edema.
Additionally, a group of thought-leading orthopaedic surgeons, including Marc Philippon, MD, and Dror Paley, MD, will share their latest clinical results and innovative techniques as part of the Daily Workshop Series in Smith & Nephew's booth (booth #1218).
For the full schedule of speakers and featured technologies, visit Smith & Nephew's dedicated AAOS meeting website www.PowerSmithNephew.com. While at the show, follow the company on Twitter (@smithnephew) and Facebook (facebook.com/smithandnephew) for regular updates.
About Smith & Nephew Smith & Nephew is a global medical technology business dedicated to helping improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma, Smith & Nephew has almost 10,500 employees and a presence in more than 90 countries. Annual sales in 2012 were more than $4.1 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).
For more information about Smith & Nephew, please visit: www.smith-nephew.com
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payors and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; strategic actions, including acquisitions and dispositions, our success in integrating acquired businesses, and disruption that may result from changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business or competitive nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors.
Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.
Trademark of Smith & Nephew. Registered US Patent and Trademark Office.
SOURCE Smith & Nephew